Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | MGD013 |
Trade Name | |
Synonyms | MGD-013|Tebotelimab |
Drug Descriptions |
MGD013 is an engineered antibody protein that targets both PDCD1 (PD-1) and LAG3 resulting in enhanced T-cell mediated anti-tumor immune response (Cancer Res July 15 2016 (76) (14 Supplement) 3217). |
DrugClasses | Immune Checkpoint Inhibitor 149 LAG3 Antibody 18 PD-L1/PD-1 antibody 121 |
CAS Registry Number | NA |
NCIT ID | C143957 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Capecitabine + Margetuximab-cmkb + MGD013 + Oxaliplatin | Capecitabine MGD013 Margetuximab-cmkb Oxaliplatin | 0 | 1 |
Fluorouracil + Leucovorin + Margetuximab-cmkb + MGD013 + Oxaliplatin | Fluorouracil Leucovorin MGD013 Margetuximab-cmkb Oxaliplatin | 0 | 1 |
Margetuximab-cmkb + MGD013 | MGD013 Margetuximab-cmkb | 0 | 0 |
MGA271 + MGD013 | MGA271 MGD013 | 0 | 1 |
MGD013 | MGD013 | 0 | 1 |